STOCK TITAN

APVO: SVP/CMO Dirk Huebner Receives 11,500 RSUs With One-Year Vest

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aptevo Therapeutics reported a compensation-related equity award to Dirk Huebner, the companys SVP and Chief Medical Officer. On 08/06/2025 Mr. Huebner was granted 11,500 Restricted Stock Units (RSUs) that convert on a one-for-one basis into common stock, reflecting a potential issuance of 11,500 shares upon settlement.

The RSUs vest in full on the first anniversary of the grant, so the shares become deliverable only after that one-year vesting period. The filing shows the ownership form as direct and the RSUs carry a $0.00 exercise/conversion price, indicating a straight equity award rather than a purchase-based option.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Officer received 11,500 RSUs that vest in one year, aligning management compensation with shareholder outcomes.

The grant of 11,500 RSUs to an executive officer is a routine equity-compensation action intended to tie senior management incentives to equity performance. The units convert one-for-one to common stock and vest in full on the first anniversary, creating a time-based retention incentive. The filing documents the award as direct beneficial ownership, with no cash exercise requirement, which is typical for restricted stock unit awards.

TL;DR: This is a standard time-vested RSU grant: 11,500 shares, one-year cliff vesting, $0 conversion cost.

From a pay-structure perspective, the award is a straightforward retention and alignment tool: 11,500 RSUs that convert 1:1 to common shares and vest in full after one year. The $0 conversion price signals a pure equity grant rather than a purchase option. The materiality of the grant depends on total share count and outstanding equity, which are not provided in this document.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Huebner Dirk

(Last) (First) (Middle)
2401 4TH AVENUE
SUITE 1050

(Street)
SEATTLE WA 98121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CMO
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 08/06/2025 A 11,500 (2) (2) Common Stock 11,500 $0 11,500 D
Explanation of Responses:
1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. The RSUs vest in full on the first anniversary of the date of grant.
/s/ SoYoung Kwon, Attorney-in-Fact 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aptevo (APVO) disclose about Dirk Huebners recent equity award?

The filing shows a grant of 11,500 Restricted Stock Units (RSUs) to Dirk Huebner, SVP and CMO, which convert one-for-one into common stock.

When do the RSUs granted to the APVO officer vest?

The RSUs vest in full on the first anniversary of the grant date.

Does the RSU award to Dirk Huebner require payment to convert into shares?

No. The RSUs have a $0.00 conversion/exercise price, indicating they convert into shares without a cash payment.

How many shares will be issued if Dirk Huebners RSUs vest?

If the RSUs vest and are settled, they would convert into 11,500 common shares on a one-for-one basis.

What ownership form is reported for the RSUs in the Form 4?

The Form 4 reports the RSUs as direct ownership following the reported transaction.
Aptevo Therapeutics Inc

NASDAQ:APVO

View APVO Stock Overview

APVO Rankings

APVO Latest News

APVO Latest SEC Filings

APVO Stock Data

4.21M
997.08k
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE